7.58
price up icon6.61%   0.47
pre-market  プレマーケット:  7.58  
loading
前日終値:
$7.11
開ける:
$7.14
24時間の取引高:
67,193
Relative Volume:
1.14
時価総額:
$26.26M
収益:
-
当期純損益:
$-31.11M
株価収益率:
-4.9542
EPS:
-1.53
ネットキャッシュフロー:
$-28.18M
1週間 パフォーマンス:
+1.61%
1か月 パフォーマンス:
-29.05%
6か月 パフォーマンス:
-44.47%
1年 パフォーマンス:
-82.00%
1日の値動き範囲:
Value
$7.14
$7.80
1週間の範囲:
Value
$7.00
$7.80
52週間の値動き範囲:
Value
$5.3495
$49.27

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name
名前
Tempest Therapeutics Inc
Name
セクター
Healthcare (1153)
Name
電話
415-798-8589
Name
住所
2000 SIERRA POINT PARKWAY, BRISBANE
Name
職員
25
Name
Twitter
Name
次回の収益日
2025-03-26
Name
最新のSEC提出書
Name
TPST's Discussions on Twitter

TPST を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
TPST
Tempest Therapeutics Inc
7.58 26.26M 0 -31.11M -28.18M -1.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-10 ダウングレード H.C. Wainwright Buy → Neutral
2025-04-10 ダウングレード Scotiabank Sector Outperform → Sector Perform
2024-03-14 開始されました Scotiabank Sector Outperform
2024-02-08 開始されました Jefferies Buy

Tempest Therapeutics Inc (TPST) 最新ニュース

pulisher
Apr 22, 2025

Tempest Therapeutics - The Pharma Letter

Apr 22, 2025
pulisher
Apr 21, 2025

Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria

Apr 21, 2025
pulisher
Apr 21, 2025

Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia

Apr 21, 2025
pulisher
Apr 21, 2025

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - GlobeNewswire

Apr 21, 2025
pulisher
Apr 21, 2025

FDA Awards Rare Disease Drug Status to Tempest's Novel FAP Treatment: Phase 2 Trial Coming in 2025 - Stock Titan

Apr 21, 2025
pulisher
Apr 13, 2025

TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up - MSN

Apr 13, 2025
pulisher
Apr 12, 2025

Scotiabank Reaffirms “Sector Perform” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

HC Wainwright Reaffirms Neutral Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger - Asianet Newsable

Apr 11, 2025
pulisher
Apr 10, 2025

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Tempest seeks strategic alternatives as cash runs out for Phase 3 trial - BioPharma Dive

Apr 10, 2025
pulisher
Apr 10, 2025

Tempest to explore alternatives to advance promising pipeline - The Pharma Letter

Apr 10, 2025
pulisher
Apr 10, 2025

HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

Tempest hits funding block for Phase III liver cancer drug-in-waiting - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial - Endpoints News

Apr 10, 2025
pulisher
Apr 09, 2025

Tempest Therapeutics evaluates strategic options amid advancements By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Tempest Therapeutics Terminates Loan Agreement with Oxford - TipRanks

Apr 09, 2025
pulisher
Apr 09, 2025

Tempest Therapeutics Mulls Alternatives to Advance Cancer Treatment Programs - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Tempest Therapeutics evaluates strategic options amid advancements - Investing.com

Apr 09, 2025
pulisher
Apr 09, 2025

Tempest Announces Plan to Explore Strategic Alternatives to - GlobeNewswire

Apr 09, 2025
pulisher
Apr 07, 2025

Tempest Therapeutics announces 1-for-13 reverse stock split - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Tempest Therapeutics announces 1-for-13 reverse stock split By Investing.com - Investing.com Canada

Apr 07, 2025
pulisher
Apr 07, 2025

Tempest Therapeutics Announced 1-For-13 Reverse Stock Split - MarketScreener

Apr 07, 2025
pulisher
Apr 05, 2025

TPST stock touches 52-week low at $0.69 amid market challenges - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

TPST stock touches 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 03, 2025

Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Update - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

Virtu Financial LLC Purchases Shares of 43,105 Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Estimate for TPST Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

FY2028 Earnings Estimate for TPST Issued By William Blair - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

HC Wainwright Has Lowered Expectations for Tempest Therapeutics (NASDAQ:TPST) Stock Price - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Scotiabank Has Lowered Expectations for Tempest Therapeutics (NASDAQ:TPST) Stock Price - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Scotiabank Lowers Tempest Therapeutics (NASDAQ:TPST) Price Target to $7.00 - Armenian Reporter

Mar 30, 2025
pulisher
Mar 29, 2025

Tempest Therapeutics (NASDAQ:TPST) Given New $16.00 Price Target at HC Wainwright - The AM Reporter

Mar 29, 2025
pulisher
Mar 28, 2025

Tempest Therapeutics Advances Cancer Therapies Amid Financial Challenges - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

H.C. Wainwright cuts Tempest Therapeutics stock target to $16 By Investing.com - Investing.com UK

Mar 28, 2025
pulisher
Mar 27, 2025

Tempest Therapeutics Inc. (TPST) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

Why Super Micro Computer Stock Was Sliding This Week - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

Tempest Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Tempest's Cancer Drug Shows 6-Month Survival Gain, Lands Major Roche Partnership - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Tempest Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView

Mar 26, 2025
pulisher
Mar 25, 2025

Tempest Announces Amezalpat Poster Presentation at the 2025 - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - Yahoo

Mar 25, 2025
pulisher
Mar 25, 2025

Breakthrough Cancer Drug Data Reveals New Immune Response Findings at AACR 2025 - Stock Titan

Mar 25, 2025
pulisher
Mar 15, 2025

Layoff Tracker: Tempest Axes 80% of Workforce - BioSpace

Mar 15, 2025
pulisher
Mar 13, 2025

Tempest Therapeutics advances Phase 2 trial for cancer prevention By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

FDA Study May Proceed Notice Received for Phase 2 Trial of - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Tempest Therapeutics Says Familial Adenomatous Polyposis Trial Gets US FDA 'Study May Proceed' Notice - Marketscreener.com

Mar 13, 2025

Tempest Therapeutics Inc (TPST) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
大文字化:     |  ボリューム (24 時間):